AXIOS February 11, 2025
The luster is starting to wear off GLP-1 weight-loss drugs including Wegovy and Ozempic as more clinicians warn patients about side effects and other potential risks stemming from their surging demand.
Why it matters: Research showing the drugs not only work for obesity but could lower the risk of heart attacks, stroke, some cancers and even Alzheimer’s disease has overshadowed the substantial cost and the fact that many patients can’t stay on them.
What they’re saying: “There is almost like a backlash kind of a sentiment going on,” said Peter Antall, chief medical officer of digital chronic health company Lark.
- “I don’t believe that we’re having second thoughts about the power of the medication. But I think the shine...
Today's Sponsors
Today's Sponsor